Home > Publications database > Full-length MSP1 is a major target of protective immunity after controlled human malaria infection. > print

001     290512
005     20240602011424.0
024 7 _ |a 10.26508/lsa.202301910
|2 doi
024 7 _ |a pmid:38803222
|2 pmid
024 7 _ |a altmetric:163741919
|2 altmetric
037 _ _ |a DKFZ-2024-01139
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Rosenkranz, Micha
|b 0
245 _ _ |a Full-length MSP1 is a major target of protective immunity after controlled human malaria infection.
260 _ _ |a Heidelberg
|c 2024
|b EMBO Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1716904786_30599
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a B Cell Immunology, German Cancer Research Center
520 _ _ |a The merozoite surface protein 1 (MSP1) is the most abundant protein on the surface of the invasive merozoite stages of Plasmodium falciparum and has long been considered a key target of protective immunity. We used samples from a single controlled human malaria challenge study to test whether the full-length version of MSP1 (MSP1FL) induced antibodies that mediated Fc-IgG functional activity in five independent assays. We found that anti-MSP1FL antibodies induced complement fixation via C1q, monocyte-mediated phagocytosis, neutrophil respiratory burst, and natural killer cell degranulation as well as IFNγ production. Activity in each of these assays was strongly associated with protection. The breadth of MSP1-specific Fc-mediated effector functions was more strongly associated with protection than the individual measures and closely mirrored what we have previously reported using the same assays against merozoites. Our findings suggest that MSP1FL is an important target of functional antibodies that contribute to a protective immune response against malaria.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Merozoite Surface Protein 1
|2 NLM Chemicals
650 _ 7 |a Antibodies, Protozoan
|2 NLM Chemicals
650 _ 7 |a Immunoglobulin G
|2 NLM Chemicals
650 _ 7 |a Interferon-gamma
|0 82115-62-6
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Merozoite Surface Protein 1: immunology
|2 MeSH
650 _ 2 |a Malaria, Falciparum: immunology
|2 MeSH
650 _ 2 |a Malaria, Falciparum: parasitology
|2 MeSH
650 _ 2 |a Plasmodium falciparum: immunology
|2 MeSH
650 _ 2 |a Antibodies, Protozoan: immunology
|2 MeSH
650 _ 2 |a Phagocytosis: immunology
|2 MeSH
650 _ 2 |a Immunoglobulin G: immunology
|2 MeSH
650 _ 2 |a Killer Cells, Natural: immunology
|2 MeSH
650 _ 2 |a Killer Cells, Natural: metabolism
|2 MeSH
650 _ 2 |a Interferon-gamma: metabolism
|2 MeSH
650 _ 2 |a Interferon-gamma: immunology
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Merozoites: immunology
|2 MeSH
650 _ 2 |a Neutrophils: immunology
|2 MeSH
650 _ 2 |a Neutrophils: metabolism
|2 MeSH
700 1 _ |a Nkumama, Irene Nailain
|0 P:(DE-He78)9725af3dc9153c1e835e9bf060f6d6f7
|b 1
700 1 _ |a Ogwang, Rodney
|b 2
700 1 _ |a Kraker, Sara
|b 3
700 1 _ |a Blickling, Marie
|0 0000-0003-0770-3449
|b 4
700 1 _ |a Mwai, Kennedy
|b 5
700 1 _ |a Odera, Dennis
|b 6
700 1 _ |a Tuju, James
|b 7
700 1 _ |a Fürle, Kristin
|0 0000-0001-6835-3759
|b 8
700 1 _ |a Frank, Roland
|b 9
700 1 _ |a Chepsat, Emily
|b 10
700 1 _ |a Kapulu, Melissa C
|b 11
700 1 _ |a Study Team, Chmi-Sika
|0 0000-0003-1142-4813
|b 12
700 1 _ |a Osier, Faith Ha
|0 0000-0001-7133-5375
|b 13
773 _ _ |a 10.26508/lsa.202301910
|g Vol. 7, no. 8, p. e202301910 -
|0 PERI:(DE-600)2948687-7
|n 8
|p e202301910 -
|t Life science alliance
|v 7
|y 2024
|x 2575-1077
909 C O |o oai:inrepo02.dkfz.de:290512
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)9725af3dc9153c1e835e9bf060f6d6f7
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LIFE SCI ALLIANCE : 2022
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-02-08T19:01:09Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-02-08T19:01:09Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2022-02-08T19:01:09Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2022-02-08T19:01:09Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-27
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-27
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-27
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-27
920 1 _ |0 I:(DE-He78)D130-20160331
|k D130
|l B-Zell-Immunologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D130-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21